Amprius Q2: $140M Revenue Keeps the Growth Story Alive-H2 Gross Margin Is the Real Test

Amprius Q2 raised the bar: demand is clearer, but execution now has to carry the story

This quarter, Amprius moved from "interesting traction" to a more serious scale-up debate. Management now expects at least $140.0 million in 2026 revenue after posting $34.0 million in Q2 revenue, up 19% sequentially and 126% year over year. That upgrade keeps the growth narrative alive.

The harder question is no longer whether there is demand. It is whether Amprius can turn that demand into durable manufacturing leverage, better economics, and enough cash generation to fund the buildout without straining the balance sheet.

What improved in Q2

The demand signal is more concrete. Amprius cited better visibility into order flow for the second half, alongside a $24.0 million order from a new European drone manufacturer and a three-year Stark Future contract expected to generate at least $100.0 million through 2029. That does not prove the trend is permanent, but it does make the case stronger than it looked a quarter ago.

The other meaningful change was margin progression. Amprius still lost money in Q2, but the company also raised its gross margin guidance to at least 28%. If that holds, investors will have better evidence that scale is starting to pay off rather than simply adding revenue on paper.

The counterweight is obvious. Operating expenses rose to $13.6 million in Q2, further increases were expected in Q3, and accounts receivable grew to $40.7 million. That combination keeps the burden of proof on management: revenue can accelerate, but the business still has to show that growth is becoming cleaner, more repeatable, and less dependent on favorable timing or customer mix.

Gross margin is the real mechanism to watch

What matters now is not just the order sheet. It is whether Amprius can turn more units into more margin per unit.

Why the margin move matters

Amprius posted GAAP gross margin of 27% in Q2, up from 20% in Q1 2026 and 9% in the same quarter last year. That improvement is the clearest sign yet that the business may be moving past the early stage where extra volume does not translate into better economics.

A second signal is that a trailing view of adjusted EBITDA nearing breakeven suggests the company is getting closer to operating leverage, not just enjoying one quarter of strong shipments.

Why H2 matters more than the headline revenue number

The core test is simple: can Amprius move from good demand to repeatable profitability? In practical terms, that means higher output with better yield, flatter fixed-cost absorption, and cleaner progress toward the company's full-year targets.

Amprius ended the quarter with $74.5 million in cash and no debt, which gives management room to work through typical manufacturing friction. But the balance sheet alone does not finish the job. Investors now need to see whether that flexibility buys real improvement in gross margin and cash conversion.

The bear case has real substance

Skeptics do not need a disaster to make their case. They only need margin gains to prove fragile, spending to rise faster than gross profit, or collections to slow enough to offset operating progress. That is why the next few quarters matter so much.

If H2 shows gross margin consistently above the current level, the growth story starts to look scalable. If not, the market may decide the stock is already pricing a future Amprius has not fully earned.

The signals that decide whether Amprius gets re-rated

Amprius is still early, but the story is no longer mostly theoretical. The company held targets for net loss below $10.0 million and positive non-GAAP Adjusted EBITDA of at least $4.0 million. That is a more credible setup than the one implied by the old "interesting but not proven" label.

What bulls need to see next

The clearest bullish signal is straightforward: gross margin holds at or above the raised full-year target as revenue keeps advancing. That would suggest Amprius is gaining manufacturing discipline rather than just shipping more cells.

Just as important is whether the company can preserve its liquidity advantage while scaling. If cash generation and margin progress continue together, investors have a stronger reason to keep backing the story.

When the thesis weakens

The bear case becomes more convincing if several warnings appear at once:

• revenue momentum slows despite management's better second-half visibility
• gross margin stalls near current levels instead of clearing the raised target
• losses widen again instead of staying on track with annual goals

If two or more of those show up, the multiple is likely to compress. If they do not, Amprius has a credible path from growth story to execution story.